Concept information
Preferred term
Daclizumab
Type
-
mesh:Descriptor
Definition
- An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
Broader concept
Entry terms
- 152923-56-3 (Daclizumab)
- CUJ2MVI71Y
- Dacliximab
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- analysis (Qualifier)
- biosynthesis (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- drug effects (Qualifier)
- economics (Qualifier)
- genetics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- physiology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- ultrastructure (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
152923-56-3 (Daclizumab)
-
CUJ2MVI71Y
URI
http://data.loterre.fr/ark:/67375/JVR-RX17C4CM-X
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}